TY - JOUR
T1 - Cost-effectiveness of nurse-led disease management for heart failure in an ethnically diverse urban community
AU - Hebert, Paul L.
AU - Sisk, Jane E.
AU - Wang, Jason J.
AU - Tuzzio, Leah
AU - Casabianca, Jodi M.
AU - Chassin, Mark R.
AU - Horowitz, Carol
AU - McLaughlin, Mary Ann
PY - 2008/10/21
Y1 - 2008/10/21
N2 - Background: Randomized, controlled trials have shown that nurse-led disease management for patients with heart failure can reduce hospitalizations. Less is known about the cost-effectiveness of these interventions. Objective: To estimate the cost-effectiveness of a nurse-led disease management intervention over 12 months, implemented in a randomized, controlled effectiveness trial. Design: Cost-effectiveness analysis conducted alongside a randomized trial. Data Sources: Medical costs from administrative records, and self-reported quality of life and nonmedical costs from patient surveys. Participants: Patients with systolic dysfunction recruited from ambulatory clinics in Harlem, New York. Time Horizon: 12 months. Perspective: Societal and payer. Intervention: 12-month program that involved 1 face-to-face encounter with a nurse and regular telephone follow-up. Outcome Measures: Quality of life as measured by the Health Utilities Index Mark 3 and EuroQol-5D and cost-effectiveness as measured by the incremental cost-effectiveness ratio (ICER). Results of Base-Case Analysis: Costs and quality of life were higher in the nurse-managed group than the usual care group. The ICERs over 12 months were $17 543 per EuroQol-5D-based quality-adjusted life-year (QALY) and $15 169 per Health Utilities Index Mark 3-based QALY (in 2001 U.S. dollars). Results of Sensitivity Analysis: From a payer perspective, the ICER ranged from $3673 to $4495 per QALY. Applying national prices in place of New York City prices yielded a societal ICER of $13 460 to $15 556 per QALY. Cost-effectiveness acceptability curves suggest that the intervention was most likely cost-effective for patients with less severe (New York Heart Association classes I to II) heart failure. Limitation: The trial was conducted in an ethnically diverse, innercity neighborhood; thus, results may not be generalizable to other communities. Conclusion: Over 12 months, the nurse-led disease management program was a reasonably cost-effective way to reduce the burden of heart failure in this community.
AB - Background: Randomized, controlled trials have shown that nurse-led disease management for patients with heart failure can reduce hospitalizations. Less is known about the cost-effectiveness of these interventions. Objective: To estimate the cost-effectiveness of a nurse-led disease management intervention over 12 months, implemented in a randomized, controlled effectiveness trial. Design: Cost-effectiveness analysis conducted alongside a randomized trial. Data Sources: Medical costs from administrative records, and self-reported quality of life and nonmedical costs from patient surveys. Participants: Patients with systolic dysfunction recruited from ambulatory clinics in Harlem, New York. Time Horizon: 12 months. Perspective: Societal and payer. Intervention: 12-month program that involved 1 face-to-face encounter with a nurse and regular telephone follow-up. Outcome Measures: Quality of life as measured by the Health Utilities Index Mark 3 and EuroQol-5D and cost-effectiveness as measured by the incremental cost-effectiveness ratio (ICER). Results of Base-Case Analysis: Costs and quality of life were higher in the nurse-managed group than the usual care group. The ICERs over 12 months were $17 543 per EuroQol-5D-based quality-adjusted life-year (QALY) and $15 169 per Health Utilities Index Mark 3-based QALY (in 2001 U.S. dollars). Results of Sensitivity Analysis: From a payer perspective, the ICER ranged from $3673 to $4495 per QALY. Applying national prices in place of New York City prices yielded a societal ICER of $13 460 to $15 556 per QALY. Cost-effectiveness acceptability curves suggest that the intervention was most likely cost-effective for patients with less severe (New York Heart Association classes I to II) heart failure. Limitation: The trial was conducted in an ethnically diverse, innercity neighborhood; thus, results may not be generalizable to other communities. Conclusion: Over 12 months, the nurse-led disease management program was a reasonably cost-effective way to reduce the burden of heart failure in this community.
UR - http://www.scopus.com/inward/record.url?scp=54549092774&partnerID=8YFLogxK
U2 - 10.7326/0003-4819-149-8-200810210-00006
DO - 10.7326/0003-4819-149-8-200810210-00006
M3 - Article
C2 - 18936502
AN - SCOPUS:54549092774
SN - 0003-4819
VL - 149
SP - 540
EP - 548
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
IS - 8
ER -